## **Dimitrios Kirmizis**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4834064/publications.pdf

Version: 2024-02-01

567281 454955 44 931 15 30 citations h-index g-index papers 44 44 44 1545 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Recommendations for the prevention, mitigation and containment of the emerging SARS-CoV-2 (COVID-19) pandemic in haemodialysis centres. Nephrology Dialysis Transplantation, 2020, 35, 737-741.	0.7	215
2	Carotid atherosclerosis is associated with inflammation and endothelial cell adhesion molecules in chronic haemodialysis patients. Nephrology Dialysis Transplantation, 2003, 18, 113-119.	0.7	111
3	Genetic Heterogeneity in Italian Families with IgA Nephropathy: Suggestive Linkage for Two Novel IgA Nephropathy Loci. American Journal of Human Genetics, 2006, 79, 1130-1134.	6.2	111
4	Effects of vitamin E-coated membrane dialyser on markers of oxidative stress and inflammation in patients on chronic haemodialysis. Nephrology Dialysis Transplantation, 2011, 26, 2296-2301.	0.7	47
5	Role of interferon- $\hat{l}^3$ gene polymorphisms in susceptibility to IgA nephropathy: a family-based association study. European Journal of Human Genetics, 2006, 14, 488-496.	2.8	43
6	Treatment of Severe IgA Nephropathy With Omegaâ€3 Fatty Acids: The Effect of a "Very Low Dose― Regimen. Renal Failure, 2004, 26, 453-459.	2.1	40
7	Sudden cardiac death in dialysis patients: different causes and management strategies. Nephrology Dialysis Transplantation, 2021, 36, 396-405.	0.7	39
8	Effects of simvastatin on markers of inflammation, oxidative stress and endothelial cell apoptosis in patients on chronic hemodialysis. Journal of Atherosclerosis and Thrombosis, 2010, 17, 1256-1265.	2.0	32
9	Should a fistula first policy be revisited in elderly haemodialysis patients?. Nephrology Dialysis Transplantation, 2019, 34, 1636-1643.	0.7	32
10	MPGN secondary to lyme disease. American Journal of Kidney Diseases, 2004, 43, 544-551.	1.9	27
11	Antiatherogenic effects of vitamin E: the search for the Holy Grail. Vascular Health and Risk Management, 2009, 5, 767.	2.3	26
12	Frontiers in hemodialysis: Innovations and technological advances. Artificial Organs, 2021, 45, 175-182.	1.9	26
13	The IgA nephropathy Biobank. An important starting point for the genetic dissection of a complex trait. BMC Nephrology, 2005, 6, 14.	1.8	24
14	Genome-wide scan identifies a copy number variable region at 3p21.1 that influences the TLR9 expression levels in IgA nephropathy patients. European Journal of Human Genetics, 2015, 23, 940-948.	2.8	23
15	Atherosclerosis and infection: is the jury still not in?. Future Microbiology, 2012, 7, 1217-1230.	2.0	22
16	The reasons for a clinical trial on incremental haemodialysis. Nephrology Dialysis Transplantation, 2020, 35, 2015-2019.	0.7	14
17	Validity of plasma fibrinogen, D-dimer, and the von Willebrand factor as markers of cardiovascular morbidity in patients on chronic hemodialysis. Medical Science Monitor, 2006, 12, CR55-62.	1.1	13
18	Incremental haemodialysis and residual kidney function: more and more observations but no trials. Nephrology Dialysis Transplantation, 2019, 34, 1806-1811.	0.7	11

#	Article	IF	CITATIONS
19	Pleiotropic vasoprotective effects of statins: The chicken or the egg?. Drug Design, Development and Therapy, 2009, 3, 191.	4.3	9
20	Exit-Site Relocation: A Novel, Straightforward Technique for Exit-Site Infections. Peritoneal Dialysis International, 2019, 39, 350-355.	2.3	8
21	Antiâ€inflammatory effects of simvastatin in diabetic compared to nonâ€diabetic patients on chronic hemodialysis (åœ¨è¿›è¡Œæ…¢æ€§è¡€æ¶²é€æžçš"ç³–å°¿ç—…æ,£è€…以åŠéžç³–å°¿ç—…æ,£è€…ä¸å⁻¹æ-"è¾›ɛ́	i¼ <mark>i.8</mark> æ±€	Ēçš" <mark>æ</mark> Š—ç, <u>Ž</u> ä
22	Sleep apnea syndrome, inflammation and oxidative stress in hemodialysis patients. Hemodialysis International, 2018, 22, 209-216.	0.9	6
23	A call to optimize haemodialysis vascular access care in healthcare disrupted by COVID-19 pandemic. Journal of Nephrology, 2021, 34, 365-368.	2.0	6
24	The walking man with a completely occluded aorta. Nephrology Dialysis Transplantation, 2004, 19, 227-229.	0.7	5
25	Impact of inflammation on antiâ€oxidative effects of vitamin <scp>E</scp> â€oated membrane dialyzer in patients on chronic hemodialysis. Hemodialysis International, 2014, 18, 751-757.	0.9	5
26	Anterior ischemic optic neuropathy in an extreme dipper dialysis patient. Hemodialysis International, 2005, 9, 143-146.	0.9	4
27	Coronary artery disease in dialysis patients: evidence synthesis, controversies and proposed management strategies. Journal of Nephrology, 2021, 34, 39-51.	2.0	4
28	Serum lipid profile constituents as markers of cardiovascular morbidity in patients on chronic hemodialysis. Biomarker Insights, 2007, 1, 185-92.	2.5	4
29	Focal Segmental Glomerulosclerosis in a Patient with Large Bilateral Asymptomatic Adrenal Myelolipomas. Renal Failure, 2003, 25, 1051-1056.	2.1	3
30	Comment on 'Membranous glomerulonephritis secondary to Borrelia burgdorferi infection presenting as nephrotic syndrome'. Nephrology Dialysis Transplantation, 2010, 25, 1723-1727.	0.7	3
31	Diagnostic accuracy of arterial line blood gas measurements as an estimate of arteriovenous fistula recirculation. Nephrology, 2013, 18, 718-723.	1.6	3
32	The effect of a single dose of BNT162b2 vaccine on the incidence of severe COVID-19 infection in patients on chronic hemodialysis: a single-centre study. Clinical and Experimental Nephrology, 2021, 26, 54.	1.6	3
33	The Effects of Vitamin E-Coated Membrane Dialyzer Compared to Simvastatin in Patients on Chronic Hemodialysis. Renal Failure, 2012, 34, 1135-1139.	2.1	2
34	POST-DIALYSIS HYPERKALAEMIA. Nephrology, 2007, 12, 205-206.	1.6	1
35	Comment on "Non-hepatitis virus-associated mixed essential cryoglobulinemia― Kidney International, 2010, 78, 113-114.	5.2	1
36	Calcium balance in hemodialysis: More uncertainty than certainty. Seminars in Dialysis, 2020, 33, 103-108.	1,3	1

#	Article	IF	CITATIONS
37	Recent advances in treatment of haemodialysis. Journal of the Royal Society of Medicine, 2021, 114, 30-37.	2.0	1
38	AGGRESSIVE CONTROL OF SECONDARY HYPERPARATHYROIDISM CAN RESULT IN IMMEDIATE EFFICIENT BLOOD PRESSURE CONTROL IN DIALYSIS PATIENTS. Nephrology, 2009, 14, 535-536.	1.6	0
39	Letter by Gavriilaki et al Regarding Article, "Bacterial Signatures in Thrombus Aspirates of Patients With Myocardial Infarction― Circulation, 2013, 128, e236.	1.6	0
40	MPGN secondary to Lyme disease: the role of cryoglobulins. CKJ: Clinical Kidney Journal, 2013, 6, 349-349.	2.9	0
41	Coxiella burnetii: a new player in atherosclerosis or an innocent bystander?. Clinical Microbiology and Infection, 2015, 21, e29.	6.0	0
42	SP440EXIT SITE RELOCATION: A NOVEL TECHNIQUE FOR EXIT SITE INFECTION. Nephrology Dialysis Transplantation, 2016, 31, i238-i238.	0.7	0
43	Vascular access malfunction: towards a more genecentric view. Clinical Nephrology, 2013, 80, 370-376.	0.7	0
44	Renal cell carcinoma in kidney transplant recipients at Guy's and King's College Hospital (UK) between 1987-2018 Journal of Clinical Oncology, 2019, 37, e16066-e16066.	1.6	0